�������ýҕ�l

It’s becoming a kind of daily ritual: President Donald Trump and a phalanx of doctors file into the White House briefing room each evening to discuss the coronavirus, producing a display of rhetorical contortions as the medical officials try to stay true to the science without crossing the president. The result can be a bewildering scene for Americans trying to understand how best to protect themselves from the virus. (Riechmann, Madhani and Lemire, 4/24)

The Trump administration's decision to sideline one of the government’s top vaccine specialists at the height of a global coronavirus pandemic has shocked scientists and science advocates who say the president is placing a greater value on loyalty to himself than on the facts and data that could save lives. The administration this week forced out Rick Bright, the head of the Biomedical Advanced Research and Development Authority and an acting deputy assistant secretary of Health and Human Services for preparedness and response. (Wilson, 4/23)

Rick Bright, an otherwise unknown federal bureaucrat, burst onto the political stage this week with allegations that the Trump White House put politics ahead of science to advance an untested malaria drug as a coronavirus treatment — explosive claims that beg the question: Why was Bright involved in decisions about the drug at all? (Florko, 4/24)

The federal scientist recently ousted from a senior position overseeing research on coronavirus vaccines felt pressured by Trump administration officials to award a $21-million contract to a Florida laboratory to study an anti-malaria drug touted by the president as a COVID-19 treatment, according to a person familiar with the incident. Rick Bright, who was abruptly removed this week from his senior post at the Department of Health and Human Services, was told by officials to approve the contract for a clinical trial of hydroxychloroquine to Alchem Laboratories, a small drug-development firm, the person said. (Cloud and Healy, 4/23)

The Trump administration pushed for nationwide access to a malaria drug touted by President Donald Trump as a Covid-19 treatment “with limited physician oversight,” according to a person familiar with the allegations of Dr. Rick Bright, the HHS vaccine chief who was ousted from his position earlier this week. Bright felt such a move was dangerous and responded by pushing for more clinical trials, the person said, but, under pressure from his superiors in the health department, eventually agreed to sign off on an emergency use authorization that allowed the Trump administration to acquire tens of millions of doses of chloroquine and hydroxychloroquine and distribute the medicines to some patients hospitalized for Covid-19. (Diamond, 4/23)

Bright's decision to go public is now exposing months of turmoil inside one of the key divisions at the Department of Health and Human Services charged with responding to the coronavirus pandemic. His allegations raise serious questions about political bias creeping into the government's response to the pandemic and the extent to which Trump's preferences for a drug overshadowed its scientific merits. (Diamond, Collins and Hoye, 4/23)